Skip to content
Oncology Research Hub

District of Columbia

Cancer clinical trials in District of Columbia

158 cancer studies are recruiting participants at sites in 1 city across District of Columbia as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every District of Columbia city with a recruiting study

By research area: Lung Cancer (48), Breast Cancer (43), Lymphoma (30), Prostate Cancer (18), Melanoma (10), Pancreatic Cancer (9).

Washington D.C. (158).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in District of Columbia

Basic details from each study's public record (the 12 most recently updated of 158). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Washington D.C.
    Registry record
    NCT05894239 · updated
  2. A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Washington D.C.
    Registry record
    NCT07748208 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Lung cancer: recently updated in District of Columbia

  1. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Teligene US
    Recruiting in
    Washington D.C.
    Registry record
    NCT05168566 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Washington D.C.
    Registry record
    NCT06287775 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Recruiting in
    Washington D.C.
    Registry record
    NCT07277413 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Recruiting in
    Washington D.C.
    Registry record
    NCT07111520 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Prostate cancer: recently updated in District of Columbia

  1. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Recruiting in
    Washington D.C.
    Registry record
    NCT04038502 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Washington D.C.
    Registry record
    NCT04423211 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Pancreatic cancer: recently updated in District of Columbia

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Recruiting in
    Washington D.C.
    Registry record
    NCT07522073 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in District of Columbia on ClinicalTrials.gov.

Ask about studies in District of Columbia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call